Why Is IONIS PHARMACEUTICAL (IONS) Stock Down Today?

IONS stock is down 4.94% to $58.30 in today’s session, marking a continuation of a recent downward trend. The stock opened with a -1.9% gap from the prior close and has since declined further, reaching a session low of $58.11. The move appears to be driven by broader market sentiment and a weak earnings profile, as the company remains unprofitable with declining revenue and a high negative net margin.

What Happened

Ionis Pharmaceuticals is scheduled to present at investor conferences on Sept. 10 and Sept. 16, with live webcasts and replays available. Despite this visibility, the stock has declined sharply. The company reported a trailing twelve-month (TTM) revenue decline of 7.4% and an EPS of -3.46, reflecting ongoing unprofitability. Meanwhile, HC Wainwright & Co. reiterated a Buy rating and a $115 price target, but this has not been enough to offset the sell-off. Retail traders and analysts are divided, with some calling the decline overdone and a potential buying opportunity. Recent insider transactions show a mix of activity, including a $1.1 million buy and $19.1 million in sales over the last 90 days.

What The Data Shows

The stock opened at $60.16 and has traded down to $58.32, with a session volume of 0.5 million shares, or 0.2 times the 3-month average. Over the last eight sessions, IONS has fallen 2.0%, from $62.04 to $60.78. The stock hit four fresh 52-week lows on Sept. 3, 2026, and currently trades near its 52-week low of $49.13. The low volume and weak fundamentals suggest the sell-off may be driven by profit-taking or broader market rotation rather than new company-specific news.

What To Watch

Ionis Pharmaceuticals has no upcoming earnings report scheduled. Investors should monitor the breadth of coverage and analyst sentiment shifts as the company continues to present at investor conferences and as the market digests its long-term financial outlook.